Alaska Medical Assistance DUR Committee Meeting
Friday, November 17, 2017
Frontier Building, 3601 C Street; Room 880
1:00pm
1.800.315.6338, access code 24251#

Agenda

(1) Review of minutes from September 2017
(2) Review of agenda
(3) Comments/Suggestions from Committee members
(4) Prospective Drug Utilization Review / Clinical Topic Areas:
   a. New Prescription Medications (Interim PA List – 6 month review)
      i. Qutenza 8% patch
   b. New Prior Authorizations, Quantity Limits, Edits
      i. Physician-administered medications
         1. HCPCS to NDC crosswalk
      ii. Viscosupplementation products (e.g., hyaluronic acid injections)
   c. Review of existing Prior Authorizations, Quantity Limits, Edits
      i. CFTR Potentiators – Kalydeco, Orkambi
      ii. Quantity limit list
      iii. 90 day medication list
      iv. Cost Exceeds Maximum
(5) Standards of Care
   a. Hemophilia
   b. Inborn Metabolic Conditions
(6) Opioids – Initiatives, Monitoring, and Updates
   a. ICD-10 Diagnosis Code on Claims, status review
   b. Dental analgesia protocol
   c. Medication Assisted Therapy
      i. Gold Star Credentialing
      ii. RetroDUR – Buprenorphine single agent
   d. Methadone
   e. Chronic Opioid Analgesic Therapy Treatment Plan requirements
   f. Retrospective Drug Utilization Review - Opioids
(7) Alternate Payment Methodology in Pharmacy
(8) Past Intervention Informational Updates
(9) FDA/DEA Updates
   a. FDA Drug Safety Communications
(10) FAERS Reports
(11) Quality Measures
(12) Trend Reports
(13) Retrospective Drug Utilization Review
   a. Stimulants and beta-blockers
   b. CFTR Potentiators, clinical outcomes
(14) End of Public Meeting

Pharmaceutical Manufacturers wishing to submit unsolicited clinical information may do so via the form found at the link below:
Submissions for the April meeting must be received no later than 3pm Alaska local time on Wednesday, November 1, 2017.